{
    "clinical_study": {
        "@rank": "85609", 
        "arm_group": [
            {
                "arm_group_label": "Gemigliptin", 
                "arm_group_type": "Experimental", 
                "description": "Gemigliptin 50mg q.d. during 7 days"
            }, 
            {
                "arm_group_label": "Irbesartan", 
                "arm_group_type": "Experimental", 
                "description": "Irbesartan 300mg q.d. during 7 days"
            }, 
            {
                "arm_group_label": "Gemiglitin + Irbesartan", 
                "arm_group_type": "Experimental", 
                "description": "Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the study is to investigate the drug interaction between Gemigliptin and\n      Irbesartan by comparing pharmacokinetics of Gemigliptin and Irbesartan administered\n      concomitantly and each alone in healthy male subjects."
        }, 
        "brief_title": "Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "-  Inclusion Criteria\n\n               -  Age between 20 to 45, healthy male subjects (at screening)\n\n               -  BMI between 18 - 27 kg/m2 (at screening)\n\n               -  Blood pressure SBP 90-140 mmHg, DBP 60-95 mmHg\n\n               -  FPG 70-125mg/dL glucose level (at screening)\n\n               -  Subject who totally understand the progress of this clinical trials, make\n                  decision by his free will, and signed a consent form to follow the\n\n          -  Exclusion Criteria\n\n               -  Subject who has past or present history of any diseases following below.(liver\n                  including hepatitis virus carrier, kidney,\n                  Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental\n                  disorder.)\n\n               -  Subject who had GI tract disease that influencable to drug absorption or(ulcer,\n                  acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not\n                  included)\n\n               -  Subject who had drug hypersensitivity reaction.(gemigliptin, irbesartan,\n                  aspirin, antibiotics)\n\n               -  Subject who already admitted in other investigator product in 80 days\n\n               -  Subject who had whole blood donation in 60 days, or component blood donation in\n                  30 days or transfusion in 30 days currently"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825850", 
            "org_study_id": "LG-GBCL001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Gemigliptin", 
                    "Gemiglitin + Irbesartan"
                ], 
                "intervention_name": "Gemigliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Irbesartan", 
                    "Gemiglitin + Irbesartan"
                ], 
                "intervention_name": "Irbesartan", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Irbesartan"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Irbesartan in Healthy Male Subjects", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate Cmax,ss of Gemigliptin and Irbesartan", 
                "measure": "Cmax,ss", 
                "safety_issue": "No", 
                "time_frame": "up to 72h post-dose"
            }, 
            {
                "description": "To evaluate AUC\u03c4,ss of Gemigliptin and Irbesartan", 
                "measure": "AUC\u03c4,ss", 
                "safety_issue": "No", 
                "time_frame": "up to 72h post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825850"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate Cmin,ss of Gemigliptin and Irbesartan", 
                "measure": "Cmin,ss", 
                "safety_issue": "No", 
                "time_frame": "up to 72h post-dose"
            }, 
            {
                "description": "To evaluate Tmax,ss of Gemigliptin, Irbesartan and LC15-0636 (active metaboilite of Gemigliptin)", 
                "measure": "Tmax,ss", 
                "safety_issue": "No", 
                "time_frame": "up to 72h post-dose"
            }, 
            {
                "description": "To evaluate Cmax,ss of LC15-0636 (active metaboilite of Gemigliptin)", 
                "measure": "Cmax,ss", 
                "safety_issue": "No", 
                "time_frame": "up to 72h post-dose"
            }, 
            {
                "description": "To evaluate AUC\u03c4,ss of LC15-0636(active metabolite of Gemigliptin)", 
                "measure": "AUC\u03c4,ss", 
                "safety_issue": "No", 
                "time_frame": "up to 72h post-dose"
            }, 
            {
                "description": "To evaluate metabolic ratio of LC15-0636(active metabolite of Gemigliptin)", 
                "measure": "metabolic ratio", 
                "safety_issue": "No", 
                "time_frame": "up to 72h post-dose"
            }
        ], 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}